| Year |
Citation |
Score |
| 2025 |
de Santiago PR, Sato S, Zhang SJ, Dougher MC, Devins KM, Bilecz AJ, Rayamajhi S, Mingo G, Rendulich HS, Feng Y, Wu C, Taylor MS, Zhuravlev Y, Jung E, Omran DK, et al. LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker. Npj Precision Oncology. 9: 62. PMID 40050409 DOI: 10.1038/s41698-025-00849-1 |
0.612 |
|
| 2023 |
Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, Feng Y, Mendez-Dorantes C, Ippoliti PJ, Hobday S, Mitchell MA, Doberstein K, Gysler SM, Hirsch MS, Schwartz L, et al. LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. Scientific Reports. 13: 1537. PMID 36707610 DOI: 10.1038/s41598-023-28840-5 |
0.591 |
|
| 2022 |
Oróstica KY, Saez-Hidalgo J, de Santiago PR, Rivas S, Contreras S, Navarro G, Asenjo JA, Olivera-Nappa Á, Armisén R. Total mutational load and clinical features as predictors of the metastatic status in lung adenocarcinoma and squamous cell carcinoma patients. Journal of Translational Medicine. 20: 373. PMID 35982500 DOI: 10.1186/s12967-022-03572-8 |
0.615 |
|
| 2022 |
Morales F, Pérez P, Tapia JC, Lobos-González L, Herranz JM, Guevara F, de Santiago PR, Palacios E, Andaur R, Sagredo EA, Marcelain K, Armisén R. Increase in ADAR1p110 activates the canonical Wnt signaling pathway associated with aggressive phenotype in triple negative breast cancer cells. Gene. 819: 146246. PMID 35122924 DOI: 10.1016/j.gene.2022.146246 |
0.493 |
|
| 2020 |
de Santiago PR, Blanco A, Morales F, Marcelain K, Harismendy O, Herrera MS, Armisén R. Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis. Life Sciences. 118956. PMID 33383047 DOI: 10.1016/j.lfs.2020.118956 |
0.63 |
|
| Show low-probability matches. |
